Stocktoria
GT Biopharma, Inc. GTBP
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2013-10-22
GT Biopharma, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | $0 | $0 |
| R&D expense | $3.5M | $5.8M | $6.5M | $8.8M | $9.6M | $485,000 | $1.7M | $9.1M | $1.1M | $975,000 |
| SG&A expense | $8.9M | $8.6M | $7.1M | $12.4M | $47.9M | $6.3M | $9.8M | $12.5M | $134.5M | $8.4M |
| Operating income | -$12.4M | -$14.4M | -$13.6M | -$21.3M | -$57.5M | -$6.8M | $16.1M | -$250.1M | -$135.6M | -$9.4M |
| Interest expense | — | — | $213,000 | $8,000 | $718,000 | -$3.0M | -$2.1M | $9.1M | $8.6M | $6.6M |
| Income tax | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Net income | -$28.4M | -$13.2M | -$7.6M | -$20.9M | -$58.0M | -$28.3M | -$38.6M | -$259.2M | -$144.2M | $9.8M |
| EPS (diluted) | $-6.68 | $-6.94 | $-5.64 | $-19.66 | — | — | — | $-5.16 | $-8.60 | $119.91 |
| Operating cash flow | -$12.9M | -$12.9M | -$8.9M | -$15.2M | -$15.6M | -$7.3M | -$3.7M | -$10.7M | -$5.4M | -$1.9M |
| Free cash flow | — | — | — | — | — | — | -$3.7M | -$10.7M | -$5.4M | -$1.9M |
| Cash & equivalents | $6.8M | $4.0M | $1.1M | $5.7M | $9.0M | $5.3M | $28,000 | $60,000 | $576,000 | $19,000 |
| Total assets | $8.1M | $4.2M | $14.1M | $16.7M | $32.2M | $5.7M | $396,000 | $25.4M | $254.4M | $25,000 |
| Total liabilities | — | — | $6.6M | $5.0M | $10.3M | — | $19.7M | $14.0M | $2.7M | $18.9M |
| Shareholders' equity | $5.8M | -$1.7M | $7.5M | $11.7M | $21.9M | -$29.4M | -$19.3M | $11.4M | $251.7M | -$18.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | — | — | — | -100.0% |
| Net income growth | — | — | — | — | — | — | — | — | -1576.0% | — |
| EPS growth | — | — | — | — | — | — | — | — | -107.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.